These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 25871620)

  • 21. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
    Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
    Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy.
    Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
    J BUON; 2013; 18(2):366-71. PubMed ID: 23818347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: comparison on cell block, needle-core, and tissue block preparations.
    Hanley KZ; Birdsong GG; Cohen C; Siddiqui MT
    Cancer; 2009 Aug; 117(4):279-88. PubMed ID: 19551847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER2 status in elderly women with breast cancer.
    Laird-Fick HS; Gardiner JC; Tokala H; Patel P; Wei S; Dimitrov NV
    J Geriatr Oncol; 2013 Oct; 4(4):362-7. PubMed ID: 24472480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reliability of histological malignancy grade, ER and HER2 status on core needle biopsy vs surgical specimen in breast cancer.
    Munch-Petersen HD; Rasmussen BB; Balslev E
    APMIS; 2014 Sep; 122(9):750-4. PubMed ID: 24372587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
    Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
    Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.
    Precht LM; Lowe KA; Atwood M; Beatty JD
    Breast J; 2010; 16(4):362-8. PubMed ID: 20443786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing the impact of polysomy-17 on HER2 status and the correlations of HER2 status with prognostic variables (ER, PR, p53, Ki-67) in epithelial ovarian cancer: a tissue microarray study using immunohistochemistry and fluorescent in situ hybridization.
    Lin CK; Lin WL; Chen FL; Lee MY; Kuo JF; Ruan A; Tyan YS; Chiang H; Chou MC; Han CP
    Int J Gynecol Pathol; 2011 Jul; 30(4):372-9. PubMed ID: 21623202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis.
    Van Belle V; Van Calster B; Brouckaert O; Vanden Bempt I; Pintens S; Harvey V; Murray P; Naume B; Wiedswang G; Paridaens R; Moerman P; Amant F; Leunen K; Smeets A; Drijkoningen M; Wildiers H; Christiaens MR; Vergote I; Van Huffel S; Neven P
    J Clin Oncol; 2010 Sep; 28(27):4129-34. PubMed ID: 20713855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic features of breast cancer differ between women in the Democratic Republic of Congo and Belgium.
    Luyeye Mvila G; Batalansi D; Praet M; Marchal G; Laenen A; Christiaens MR; Brouckaert O; Ali-Risasi C; Neven P; Van Ongeval C
    Breast; 2015 Oct; 24(5):642-8. PubMed ID: 26279132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer.
    Park SY; Kim KS; Lee TG; Park SS; Kim SM; Han W; Noh DY; Kim SW
    Am J Surg; 2009 Feb; 197(2):266-9. PubMed ID: 18614146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
    Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
    J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
    Petit T; Wilt M; Velten M; Rodier JF; Fricker JP; Dufour P; Ghnassia JP
    Breast Cancer Res Treat; 2010 Nov; 124(2):387-91. PubMed ID: 20824324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utility of estrogen receptor, progesterone receptor, and HER-2/neu analysis of multiple foci in multifocal ipsilateral invasive breast carcinoma.
    East EG; Pang JC; Kidwell KM; Jorns JM
    Am J Clin Pathol; 2015 Dec; 144(6):952-9. PubMed ID: 26573003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer.
    Mann GB; Fahey VD; Feleppa F; Buchanan MR
    J Clin Oncol; 2005 Aug; 23(22):5148-54. PubMed ID: 16051956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reliability of Prognostic and Predictive Factors Evaluated by Needle Core Biopsies of Large Breast Invasive Tumors.
    Petrau C; Clatot F; Cornic M; Berghian A; Veresezan L; Callonnec F; Baron M; Veyret C; Laberge S; Thery JC; Picquenot JM
    Am J Clin Pathol; 2015 Oct; 144(4):555-62. PubMed ID: 26386076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of biomarkers in multifocal/multicentric invasive breast carcinomas.
    Pekmezci M; Szpaderska A; Osipo C; Erşahin Ç
    Int J Surg Pathol; 2013 Apr; 21(2):126-32. PubMed ID: 23204031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
    Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
    Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ER and PR immunohistochemistry and HER2 FISH versus oncotype DX: implications for breast cancer treatment.
    Park MM; Ebel JJ; Zhao W; Zynger DL
    Breast J; 2014; 20(1):37-45. PubMed ID: 24261318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.